Consistent with above, previous reports have highlighted that increase in levels and addiction to MCL1 and/or Bcl-xL confers innate or acquired resistance to venetoclax in leukemia and lymphoma cells (Fig. 7)29,30. Here, BCL2L1 is linked to leukemia.